Shares of Bristol-Myers Squibb Co (NYSE:BMY) have received a consensus recommendation of “Hold” from the nineteen analysts that are covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a sell rating, eight have given a hold rating and eight have assigned a buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $66.05.
A number of analysts have weighed in on BMY shares. Zacks Investment Research raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $68.00 target price for the company in a research report on Wednesday, November 1st. SunTrust Banks raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research report on Monday, October 30th. Citigroup set a $72.00 target price on shares of Bristol-Myers Squibb and gave the company a “buy” rating in a research report on Tuesday, December 5th. Credit Suisse Group set a $62.00 price objective on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Monday, January 22nd. Finally, Vetr downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $59.70 price objective for the company. in a research report on Friday, December 22nd.
In other news, Director Theodore R. Samuels II bought 4,000 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The shares were bought at an average cost of $62.30 per share, for a total transaction of $249,200.00. Following the acquisition, the director now directly owns 22,000 shares in the company, valued at $1,370,600. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of the stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total value of $335,172.00. Following the completion of the transaction, the executive vice president now owns 9,251 shares in the company, valued at $585,033.24. The disclosure for this sale can be found here. 0.23% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently modified their holdings of the stock. Cambridge Investment Research Advisors Inc. lifted its stake in Bristol-Myers Squibb by 11.4% during the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 209,528 shares of the biopharmaceutical company’s stock valued at $12,840,000 after acquiring an additional 21,391 shares in the last quarter. Ackerman Capital Advisors LLC bought a new position in Bristol-Myers Squibb during the 4th quarter valued at $211,000. Fairfield Bush & CO. lifted its stake in Bristol-Myers Squibb by 17.2% during the 4th quarter. Fairfield Bush & CO. now owns 20,855 shares of the biopharmaceutical company’s stock valued at $1,278,000 after acquiring an additional 3,059 shares in the last quarter. D.B. Root & Company LLC bought a new position in Bristol-Myers Squibb during the 4th quarter valued at $1,072,000. Finally, Colonial Trust Advisors lifted its stake in Bristol-Myers Squibb by 38.5% during the 4th quarter. Colonial Trust Advisors now owns 10,703 shares of the biopharmaceutical company’s stock valued at $656,000 after acquiring an additional 2,974 shares in the last quarter. Institutional investors own 69.82% of the company’s stock.
Bristol-Myers Squibb (NYSE:BMY) traded down $0.79 during trading hours on Tuesday, reaching $67.84. 4,122,989 shares of the company’s stock were exchanged, compared to its average volume of 8,563,402. The firm has a market cap of $111,520.00, a P/E ratio of 28.75, a PEG ratio of 2.11 and a beta of 1.08. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.55 and a quick ratio of 1.43. Bristol-Myers Squibb has a twelve month low of $51.56 and a twelve month high of $70.05.
Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.01. The business had revenue of $5.45 billion during the quarter, compared to the consensus estimate of $5.35 billion. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 35.43%. The company’s revenue for the quarter was up 3.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.63 EPS. research analysts expect that Bristol-Myers Squibb will post 3.21 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Thursday, February 1st. Investors of record on Friday, January 5th were issued a $0.40 dividend. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.36%. The ex-dividend date was Thursday, January 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 67.80%.
ILLEGAL ACTIVITY NOTICE: “Bristol-Myers Squibb Co (BMY) Given Average Recommendation of “Hold” by Brokerages” was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://ledgergazette.com/2018/03/14/bristol-myers-squibb-co-bmy-given-average-recommendation-of-hold-by-brokerages.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.